BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1445 related articles for article (PubMed ID: 17201457)

  • 1. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.
    Abd Rahman AN; Tett SE; Staatz CE
    Clin Pharmacokinet; 2013 May; 52(5):303-31. PubMed ID: 23475567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
    Staatz CE; Tett SE
    Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR; Ekberg H; Grinyó J; Nashan B; Vincenti F; Snell P; Mamelok RD; Bouw RM
    Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC; van Gelder T; Sombogaard F; Shaw LM; van Hest RM; Mathot RA
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.
    de Winter BC; Monchaud C; Prémaud A; Pison C; Kessler R; Reynaud-Gaubert M; Dromer C; Stern M; Guillemain R; Knoop C; Estenne M; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Jan; 51(1):29-39. PubMed ID: 22054177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Oellerich M; Shipkova M; Schütz E; Wieland E; Weber L; Tönshoff B; Armstrong VW
    Ther Drug Monit; 2000 Feb; 22(1):20-6. PubMed ID: 10688252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation.
    Stracke S; Shipkova M; Mayer J; Keller F; Zarghom A; Yang L; Henne-Bruns D; Wieland E
    Clin Transplant; 2012; 26(1):57-66. PubMed ID: 21299636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
    Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
    Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?
    Abd Rahman AN; Tett SE; Staatz CE
    Clin Pharmacokinet; 2014 Mar; 53(3):227-245. PubMed ID: 24327238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteric-coated mycophenolate sodium for transplant immunosuppression.
    Ingle GR; Shah T
    Am J Health Syst Pharm; 2005 Nov; 62(21):2252-9. PubMed ID: 16239415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.